New Triple-Action antibody takes on Hard-to-Treat cancers
NCT ID NCT07055594
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 41 times
Summary
This study tests a new drug called SOA101, a special antibody that grabs onto cancer cells and helps the immune system attack them. It is for people with advanced solid tumors (like lung, ovarian, or breast cancer) who have no other good treatment options. The trial will first find the safest dose, then check if the drug shrinks tumors. About 76 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
China Medical University Hospital
RECRUITINGTaichung, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SOA101 (a trispecific antibody that targets cancer cells and engages immune cells)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 76 participants, so the drug may not prove effective or safe enough for wider use. Side effects from immune activation are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.